Aminoglycosides Market Report 2025

The aminoglycosides market size has grown steadily in recent years. It will grow from $1.84 billion in 2024 to $1.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to antibiotic discovery and development, advancements in medicinal chemistry, clinical effectiveness in treating gram-negative infections, broad-spectrum antibacterial activity, hospital-acquired infection control, global population growth, post-surgery infection prevention, research and development investments.

The aminoglycosides market size is expected to see strong growth in the next few years. It will grow to $2.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancements in antibiotic stewardship, personalized medicine approaches, innovations in drug delivery, global spread of antibiotic-resistant strains, increasing focus on rare diseases, expanding applications in dermatology, patient education on antibiotic use. Major trends in the forecast period include biotechnological innovations, combination therapies, technological advancements in production, price competition.

The aminoglycosides market is anticipated to witness growth due to the escalating incidences of animal disease outbreaks. These outbreaks significantly impact the normal functions of animals and create a demand for aminoglycosides, like amikacin and gentamicin, widely used in veterinary medicine. A recent example is the anthrax outbreak reported and monitored in remote areas of Canada's Wood Buffalo National Park in July 2022. This trend is expected to continue, further boosting the demand for aminoglycosides within the market.

The growing ownership of pets is poised to fuel the expansion of the aminoglycosides market. The increased number of pet owners, who are responsible for the care and well-being of animals kept as companions, contributes to the market's growth by expanding the customer base. This surge in pet ownership encourages preventive healthcare practices for pets and drives investments in veterinary pharmaceuticals, including aminoglycosides, to address various health needs. An example of this growth is evident in the UK, where approximately 57% of households, totaling 16.2 million, have 38 million pets, as reported by Improve International in March 2023. This rise in pet ownership remains a driving force behind the growth of the aminoglycosides market.

Process innovation is a significant trend in the aminoglycosides market, with major companies focusing on new process solutions to enhance their competitive position. For example, in February 2024, Cipla Limited, an India-based pharmaceutical company, received approval from the Central Drugs Standard Control Organization (CDSCO) for ZEMDRI (plazomicin), an intravenous aminoglycoside antibiotic. This antibiotic is specifically indicated for treating complicated urinary tract infections (cUTIs), including pyelonephritis.

Major companies in the aminoglycosides market are concentrating on developing innovative products, including active ingredients that are effective against specific bacterial pathogens. An active ingredient is the chemical component within a product, such as a drug or pesticide, that produces the desired therapeutic or biological effect. For example, in July 2023, Bimeda US, a U.S.-based animal health company, launched SpectoGard, an injectable solution designed to treat various bacterial infections in cattle. This product contains spectinomycin sulfate, an antibiotic used for treating bovine respiratory disease (BRD) caused by particular bacterial pathogens. The solution offers veterinarians and cattle producers in the U.S. a convenient treatment option to enhance herd health. Its FDA status underscores its safety and efficacy for livestock use.

In April 2022, Animal Dermatology Group Inc., a US-based veterinary company, executed the acquisition of Austin Veterinary Dermatology & Allergy. The strategic acquisition, completed for an undisclosed amount, is part of Animal Dermatology Group's ongoing efforts to expand its geographic presence and consolidate its market position. Through this acquisition, the company aims to broaden its scope and offer top-tier treatment for skin diseases across more regions. This move reinforces Animal Dermatology Group's commitment to enhancing its expertise in veterinary dermatology. Austin Veterinary Dermatology & Allergy, a US-based biotechnology company, aligns well with the expansion goals of Animal Dermatology Group.

Major companies operating in the aminoglycosides market are Kremoint Pharma Pvt. Ltd., Vega Pharma Ltd., Jiangxi Bolai Pharmacy Co. Ltd., Xian Wison Biological Technology Co. Ltd., Hangzhou Uniwise International Co. Ltd., HuvePharma Inc., Yi Chang Veterinary Medicine Factory, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd., Cipla Limited, Pfizer Inc., Allergan PLC, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Novartis AG, Johnson & Johnson Inc., Bristol Myers Squibb Company, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifescience limited, Lupin Limited, Aurobindo Pharma Limited, Fresenius Kabi AG, Aspen Pharmacare Holdings Limited, Mylan N.V., Sanofi SA, Wyeth Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., GlaxoSmithKline plc.

Asia-Pacific was the largest region in the aminoglycosides market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the aminoglycosides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aminoglycosides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aminoglycosides, a class of antibiotics renowned for their ability to impede protein synthesis, play a crucial role in treating infections caused by aerobic gram-negative bacilli. These infections commonly manifest in the abdomen and urinary tract, as well as in cases of bacteremia and endocarditis.

Among the primary products in the aminoglycoside category are neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others. Neomycin, for instance, is specifically employed to prevent bacterial infections in the intestines. Derived from the metabolic products of Streptomyces fradiae, neomycin is recognized as a broad-spectrum aminoglycoside antibiotic. Aminoglycosides are administered through various routes, including injectables (parenteral), feed, intra-mammary, topical, and oral applications. Their use extends across veterinary medicine, addressing conditions such as skin infections, respiratory diseases, urinary tract infections, pelvic diseases, and various other ailments.

The aminoglycosides market research report is one of a series of new reports that provides aminoglycosides market statistics, including aminoglycosides industry global market size, regional shares, competitors with an aminoglycosides market share, detailed aminoglycosides market segments, market trends and opportunities, and any further data you may need to thrive in the aminoglycosides industry. This aminoglycosides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aminoglycosides market consists of sales of plazomicin and netilmicin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.